This is a 4-week comparison study between the intervention and control sides of the face. Purposive sampling to recruit 13 patients with seborrheic dermatitis will be conducted in this study. The study will start after researcher has been granted the Ethic Committee Approval. The process of subject recruitment and clinical data collection will take place at the Outpatient Department (OPD) while photograph taking and skin measurement will take place at Laser Center and Bioengineering Department, respectively. All bioengineering instruments will be operated under the climate controlled environment; i.e, at temperature 20+/-2 degree Celsius and 50+/-2 % of relative humidity. A subject must get acclimatized to the ambient atmosphere for at least 30 minutes. The clinical data, skin barrier function, the quality of life, subject's satisfaction scale will be collected at the first day (D0, as baseline) and 4th week after finishing the test product (Wk4).

Inclusion Criteria

• Age: ≥ 18 years old
• Gender: Male and Female
• Patient who never uses or has stopped using topical corticosteroids/calcineurin inhibitor or other topical treatments exerting anti-inflammatory action (on the face) more than 2 weeks before entering this clinical trials.
• Patient who does not use cosmetic containing any oxidants or others that exert anti-oxidant effect(s). If there is any, one must refrain from using them more than 2 weeks before entering this clinical trials.

Exclusion Criteria

• Patients with known cases of underlying HIV/AIDS, neurological condition e.g., Parkinson's disease.
• Patient associated with any autoimmune diseases and other skin diseases
• Patient takes any forms of oral immunotherapy more than 2 months up to the first day of clinical trials.
• Patients continuously use of topical corticosteroids or other anti-inflammatory medicines on regular basis up to the first day of clinical trial.
• Patient who refuses to stop using cosmetic(s) containing anti-oxidants or those exert anti-oxidant effect(s).
• Patient who is allergic to the test product or one of its ingredients.
• Pregnancy or nursing woman

We are not allowed to share IPD without participants' permission in advance.